ProPhase Labs, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
ProPhase Labs, Inc. (PRPH) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $2.74 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-19
- ProPhase Labs, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $1.17M, a 39.69% increase year-over-year.
- ProPhase Labs, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $1.56M.
- ProPhase Labs, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$1.29M, a 623.17% decline year-over-year.
- ProPhase Labs, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $117.00K, a 87.34% decline year-over-year.
- ProPhase Labs, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$722.00K, a 114.25% decline from fiscal 2024.
- ProPhase Labs, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $5.07M, a 77.01% increase from fiscal 2023.
- ProPhase Labs, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $2.86M.
- ProPhase Labs, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$1.12M, a 145.76% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.17M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $2.74M 10-Q · filed 2026-08-19 | $1.45M derived: sum of 3 quarters · filed 2026-08-19 | $1.57M derived: sum of 4 quarters · filed 2026-08-19 | ||||
| 2026-03-31 | $1.56M 10-Q/A · filed 2026-07-09 | $1.18M 10-Q · filed 2026-06-30 | $278.00K derived: sum of 2 quarters · filed 2026-07-09 | $395.00K derived: sum of 3 quarters · filed 2026-07-09 | $1.23M derived: sum of 4 quarters · filed 2026-08-19 | |||
| 2025-12-31 | -$1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | -$1.17M derived: sum of 2 quarters · filed 2026-06-01 | -$331.00K derived: sum of 3 quarters · filed 2026-08-19 | -$722.00K 10-K · filed 2026-06-01 | ||||
| 2025-09-30 | $117.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $956.00K derived: sum of 2 quarters · filed 2026-08-19 | $565.00K 10-Q · filed 2025-11-19 | $811.00K derived: sum of 4 quarters · filed 2026-08-19 | ||||
| 2025-06-30 | $839.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $448.00K 10-Q · filed 2026-08-19 | $694.00K derived: sum of 3 quarters · filed 2026-08-19 | $1.62M derived: sum of 4 quarters · filed 2026-08-19 | ||||
| 2025-03-31 | -$391.00K 10-Q/A · filed 2026-07-09 | -$145.00K derived: sum of 2 quarters · filed 2026-07-09 | $779.00K derived: sum of 3 quarters · filed 2026-07-09 | $2.13M derived: sum of 4 quarters · filed 2026-07-09 | ||||
| 2024-12-31 | $246.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $1.17M derived: sum of 2 quarters · filed 2026-06-01 | $2.52M derived: sum of 3 quarters · filed 2026-06-01 | $5.07M 10-K · filed 2026-06-01 | ||||
| 2024-09-30 | $924.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $2.28M derived: sum of 2 quarters · filed 2025-11-19 | $4.82M 10-Q · filed 2025-11-19 | $6.07M 10-Q · filed 2024-11-13 | $8.12M derived: sum of 4 quarters · filed 2025-11-19 | |||
| 2024-06-30 | $1.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $3.90M 10-Q · filed 2025-08-13 | $4.25M 10-Q · filed 2024-08-14 | $7.20M derived: sum of 3 quarters · filed 2025-08-13 | $7.88M derived: sum of 4 quarters · filed 2025-08-13 | |||
| 2024-03-31 | $2.54M 10-Q · filed 2025-05-20 | $2.38M 10-Q · filed 2024-05-10 | $5.84M derived: sum of 2 quarters · filed 2025-05-20 | $6.52M derived: sum of 3 quarters · filed 2025-05-20 | $8.06M derived: sum of 4 quarters · filed 2025-05-20 | |||
| 2023-12-31 | $3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $3.98M derived: sum of 2 quarters · filed 2025-04-01 | $5.52M derived: sum of 3 quarters · filed 2025-04-01 | $2.86M 10-K · filed 2025-04-01 | $3.48M 10-K · filed 2024-03-29 | |||
| 2023-09-30 | $681.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $2.22M derived: sum of 2 quarters · filed 2024-11-13 | -$438.00K 10-Q · filed 2024-11-13 | |||||
| 2023-06-30 | $1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$1.12M 10-Q · filed 2024-08-14 | ||||||
| 2023-03-31 | -$2.66M 10-Q · filed 2024-05-10 | |||||||
| 2022-12-31 | -$1.12M 10-K · filed 2024-03-29 | |||||||
| 2022-03-31 | $1.18M 10-Q · filed 2022-05-13 | $5.38M derived: sum of 2 quarters · filed 2023-03-29 | $285.00K derived: sum of 3 quarters · filed 2023-03-29 | -$381.00K derived: sum of 4 quarters · filed 2023-03-29 | ||||
| 2021-12-31 | $4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$893.00K derived: sum of 2 quarters · filed 2023-03-29 | -$1.56M derived: sum of 3 quarters · filed 2023-03-29 | $2.45M 10-K · filed 2023-03-29 | ||||
| 2021-09-30 | -$5.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$5.76M derived: sum of 2 quarters · filed 2021-11-12 | -$1.75M 10-Q · filed 2021-11-12 | $1.12M derived: sum of 4 quarters · filed 2022-05-13 | ||||
| 2021-06-30 | -$666.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $3.34M 10-Q · filed 2021-08-13 | $6.21M derived: sum of 3 quarters · filed 2022-05-13 | $6.27M derived: sum of 4 quarters · filed 2022-05-13 | ||||
| 2021-03-31 | $4.01M 10-Q · filed 2022-05-13 | $6.88M derived: sum of 2 quarters · filed 2022-05-13 | $6.94M derived: sum of 3 quarters · filed 2022-05-13 | $7.08M derived: sum of 4 quarters · filed 2022-05-13 | ||||
| 2020-12-31 | $2.87M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $2.93M derived: sum of 2 quarters · filed 2022-03-31 | $3.08M derived: sum of 3 quarters · filed 2022-03-31 | $3.34M 10-K · filed 2022-03-31 | $339.00K 10-K · filed 2021-03-31 | |||
| 2020-09-30 | $58.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $207.00K derived: sum of 2 quarters · filed 2021-11-12 | $470.00K 10-Q · filed 2021-11-12 | $286.00K derived: sum of 4 quarters · filed 2021-11-12 | ||||
| 2020-06-30 | $149.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $412.00K 10-Q · filed 2021-08-13 | $228.00K derived: sum of 3 quarters · filed 2021-08-13 | $355.00K derived: sum of 4 quarters · filed 2021-08-13 | ||||
| 2020-03-31 | $263.00K 10-Q · filed 2021-05-14 | $79.00K derived: sum of 2 quarters · filed 2021-05-14 | $206.00K derived: sum of 3 quarters · filed 2021-05-14 | $428.00K derived: sum of 4 quarters · filed 2021-05-14 | ||||
| 2019-12-31 | -$184.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$57.00K derived: sum of 2 quarters · filed 2021-03-31 | $165.00K derived: sum of 3 quarters · filed 2021-03-31 | -$14.00K 10-K · filed 2021-03-31 | ||||
| 2019-09-30 | $127.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-19 | $349.00K derived: sum of 2 quarters · filed 2020-11-19 | $170.00K 10-Q · filed 2020-11-19 | $340.00K derived: sum of 4 quarters · filed 2020-11-19 | ||||
| 2019-06-30 | $222.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $43.00K 10-Q · filed 2020-08-11 | $213.00K derived: sum of 3 quarters · filed 2020-08-11 | $137.00K derived: sum of 4 quarters · filed 2020-08-11 | ||||
| 2019-03-31 | -$179.00K 10-Q · filed 2020-05-12 | -$9.00K derived: sum of 2 quarters · filed 2020-05-12 | -$85.00K derived: sum of 3 quarters · filed 2020-05-12 | -$286.00K derived: sum of 4 quarters · filed 2020-05-12 | ||||
| 2018-12-31 | $170.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $94.00K derived: sum of 2 quarters · filed 2020-03-26 | -$107.00K derived: sum of 3 quarters · filed 2020-03-26 | -$125.00K 10-K · filed 2020-03-26 | ||||
| 2018-09-30 | -$76.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$277.00K derived: sum of 2 quarters · filed 2019-11-12 | -$295.00K 10-Q · filed 2019-11-12 | -$182.00K 10-Q · filed 2018-11-14 | -$236.00K derived: sum of 4 quarters · filed 2019-11-12 | |||
| 2018-06-30 | -$201.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | -$219.00K 10-Q · filed 2019-08-12 | -$160.00K derived: sum of 3 quarters · filed 2019-08-12 | |||||
| 2018-03-31 | -$18.00K 10-Q · filed 2019-05-14 | $41.00K derived: sum of 2 quarters · filed 2019-05-14 | ||||||
| 2017-12-31 | $59.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | -$1.59M 10-K · filed 2019-03-26 | ||||||
| 2017-09-30 | -$1.65M 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |